

Table 9.21
Hodgkin LymphomaEstimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b		> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>									
All Races	Both Sexes	37,871	34,834	31,045	26,309	22,612	152,671	62,860	215,531	
	Males	21,103	18,693	15,900	13,296	11,208	80,200	30,566	110,766	
	Females	16,768	16,140	15,145	13,013	11,404	72,471	32,294	104,765	
White	Both Sexes	30,738	28,984	26,160	22,837	19,902	128,619	59,871	188,491	
	Males	17,198	15,626	13,547	11,517	9,940	67,828	30,377	98,206	
	Females	13,540	13,358	12,613	11,319	9,961	60,791	29,494	90,285	
Black	Both Sexes	5,116	4,343	3,700	2,695	2,188	18,042	5,210	23,252	
	Males	2,779	2,296	1,722	1,327	1,040	9,164	3,405	12,569	
	Females	2,337	2,047	1,978	1,368	1,148	8,878	1,806	10,683	
Asian/ Pacific Islander	Both Sexes	1,133	963	766	466	286	3,614	+	+	
	Males	615	485	373	256	103	1,831	+	+	
	Females	518	478	392	211	183	1,782	+	+	
Hispanic	Both Sexes	4,969	4,134	3,161	2,590	1,640	16,495	+	+	
	Males	2,761	2,163	1,740	1,422	897	8,982	+	+	
	Females	2,208	1,971	1,421	1,168	744	7,512	+	+	

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race	Sex											
All Races	Both Sexes	0.0471	0.0006	0.0101	0.0423	0.0733	0.0830	0.0674	0.0535	0.0491	0.0396	0.0467
	Males	0.0502	0.0009	0.0114	0.0438	0.0699	0.0854	0.0755	0.0644	0.0598	0.0485	0.0497
	Females	0.0441	0.0003	0.0086	0.0406	0.0767	0.0807	0.0596	0.0436	0.0402	0.0341	0.0441
White	Both Sexes	0.0508	0.0005	0.0103	0.0460	0.0798	0.0894	0.0711	0.0560	0.0522	0.0426	0.0501
	Males	0.0541	0.0007	0.0112	0.0481	0.0751	0.0917	0.0789	0.0668	0.0628	0.0520	0.0528
	Females	0.0476	0.0003	0.0093	0.0437	0.0847	0.0871	0.0635	0.0460	0.0432	0.0367	0.0478
Black	Both Sexes	0.0396	0.0009	0.0098	0.0339	0.0622	0.0770	0.0651	0.0504	0.0367	0.0233	0.0414
	Males	0.0419	0.0018	0.0122	0.0322	0.0615	0.0769	0.0760	0.0629	0.0499	0.0329	0.0447
	Females	0.0375	-	0.0073	0.0356	0.0629	0.0771	0.0556	0.0404	0.0274	0.0184	0.0387
Asian/ Pacific Islander	Both Sexes	0.0173	0.0005	0.0077	0.0202	0.0291	0.0247	0.0186	0.0163	0.0159	0.0107	0.0165
	Males	0.0183	0.0008	0.0106	0.0228	0.0300	0.0231	0.0193	0.0165	0.0226	0.0106	0.0177
	Females	0.0164	-	0.0047	0.0175	0.0283	0.0260	0.0179	0.0161	0.0105	0.0108	0.0155
Hispanic	Both Sexes	0.0284	0.0005	0.0088	0.0312	0.0461	0.0453	0.0408	0.0444	0.0490	0.0409	0.0315
	Males	0.0306	0.0008	0.0097	0.0336	0.0451	0.0485	0.0459	0.0557	0.0573	0.0574	0.0347
	Females	0.0261	0.0002	0.0078	0.0287	0.0472	0.0421	0.0357	0.0343	0.0426	0.0306	0.0287

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years.

^c Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^d Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^e Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.